David Malcom Rodman Sells 11,366 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 11,366 shares of the business's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $14.53, for a total value of $165,147.98. Following the transaction, the insider now directly owns 111,686 shares of the company's stock, valued at approximately $1,622,797.58. This represents a 9.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

David Malcom Rodman also recently made the following trade(s):

• On Tuesday, April 1st, David Malcom Rodman sold 55,771 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $15.76, for a total transaction of $878,950.96.

Mineralys Therapeutics Trading Down 1.1 %

Shares of NASDAQ:MLYS traded down $0.15 during midday trading on Friday, hitting $13.35. 382,306 shares of the stock were exchanged, compared to its average volume of 416,447. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38. The company has a 50 day moving average price of $12.59 and a 200-day moving average price of $12.36. The stock has a market cap of $866.09 million, a P/E ratio of -3.67 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. On average, equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Institutional Trading of Mineralys Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MLYS. BNP Paribas Financial Markets purchased a new position in Mineralys Therapeutics in the fourth quarter valued at approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of Mineralys Therapeutics during the fourth quarter valued at approximately $128,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Mineralys Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock valued at $130,000 after purchasing an additional 989 shares during the period. GAMMA Investing LLC grew its holdings in Mineralys Therapeutics by 9,602.2% during the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock valued at $140,000 after purchasing an additional 8,738 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Mineralys Therapeutics during the 4th quarter worth $145,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on MLYS shares. Guggenheim reaffirmed a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th. The Goldman Sachs Group reduced their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a report on Thursday, February 13th. Finally, HC Wainwright raised their price target on Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a "buy" rating in a research note on Wednesday, April 2nd.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.